Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study evaluating effect of food on Pharmacokinetics of Ertugliflozin/Sitagliptin fixed dose combination tablet in healthy volunteers

Next Previous
X
Search
Trial Profile

A study evaluating effect of food on Pharmacokinetics of Ertugliflozin/Sitagliptin fixed dose combination tablet in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ertugliflozin/sitagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 06 Apr 2017 New trial record
    • 18 Mar 2017 Results (n=42) assessing effect of food on pharmacokinetics of Ertugliflozin and its FDCs using patient data from this and other two trials, (See CTPs 283404, 283430), presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top